This article describes a patient who developed Harada disease-like uveitis after quadrivalent human papillomavirus (HPV4) vaccination and experienced resolution without any systemic treatment. To achieve this aim, a case report and a review of related literature on HPV vaccination causing uveitis were conducted. The results of this study show a diagnosis of Harada disease-like uveitis after HPV4 vaccination based on the vaccination history, clinical symptoms, and multimodal imaging. Resolution without any systemic corticosteroid treatment was observed. According to these findings, patients may develop uveitis with Harada-like features, which can be a mild and self-limiting process, after HPV4 vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920230 | PMC |
| http://dx.doi.org/10.1080/21645515.2021.1953349 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: Nivolumab can cause various immune-related adverse events; it rarely induces Vogt-Koyanagi-Harada-disease-like uveitis. Vogt-Koyanagi-Harada-disease is reported to be closely associated with human leukocyte antigen-DR4.
Case Presentation: A 68-year-old man with metastatic renal cancer underwent nephrectomy.
Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis.
Invest New Drugs
October 2024
College of pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.
Pembrolizumab has been associated with episodes of uveitis, and the clinical characteristics between them are unknown. The aim of this study was to investigate the clinical characteristics of pembrolizumab-induced uveitis and to provide reference for prevention, diagnosis and treatment. We collected studies related to pembrolizumab-induced uveitis by searching databases for retrospective analysis until April 30, 2024.
View Article and Find Full Text PDFA Case of Vogt-Koyanagi-Harada Disease and Retinal Peri-Phlebitis in a Patient With Presumed Ocular Tuberculosis.
Cureus
July 2024
Ophthalmology, Al Shifa Trust Eye Hospital, Rawalpindi, PAK.
A middle-aged hypertensive female presented with headaches, tinnitus, and blurred vision for two weeks. Clinical examination revealed mild vitritis and bilateral multifocal exudative detachments at the posterior pole, together with peripheral vascular cuffing and peri-phlebitis. Laboratory testing pointed towards isolated presumed intraocular tuberculosis (IOTB) as the probable cause.
View Article and Find Full Text PDFDevelopment of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
BMC Ophthalmol
June 2024
Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) can lead to Vogt-Koyanagi-Harada disease (VKHD)-like uveitis, but this is the first report linking a new PD-1 monoclonal antibody, Toripalimab, to such adverse effects.
- A case is presented where a patient developed severe binocular acute panuveitis and exudative retinal detachment after completing 20 months of Toripalimab treatment for bladder cancer.
- The patient's eye condition improved following discontinuation of ICIs and treatment with corticosteroids, highlighting the need for vigilance regarding eye complications in long-term PD-1 therapy.
Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04.
J Dermatol
June 2024
Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
The combination of BRAF kinase inhibitors (BRAFis) and MEK kinase inhibitors (MEKis) is one of the most promising chemotherapy regimens in the treatment of BRAF-mutant melanoma. Although BRAFi plus MEKi combined therapy is widely used for the treatment of BRAF-mutated melanoma, the incidence of uveitis caused by BRAFi plus MEKi is limited. In this report, we described five cases (two men and three women) of Vogt-Koyanagi-Harada (VKH) disease-like uveitis in melanoma patients who received BRAFi plus MEKi combined therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!